FOR AUTHORS
Search
Search Results
##search.searchResults.foundPlural##
-
PO-86 | CGRP, VIP and PACAP plasmatic levels in migraine patients before and after anti-CGRP(R) monoclonal antibodies prophylaxis Alessia Bellotti,1 Davide Chiasserini,2 Alfredo Megaro,2 Daniela Fruttini,3 Pierluigi Navarra,4 Giuseppe Tringali,4 Paolo Calabresi,5 Lucilla Parnetti,1 Paola Sarchielli1 | 1Department of Medicine and Surgery, Section of Neurology, University of Perugia, Perugia, Italy; 2Department of Medicine and Surgery, Section of Physiology and Biochemistry, University of Perugia, Perugia, Italy; 3Department of Medicine and Surgery, Section of Internal Medicine, University of Perugia, Perugia, Italy; 4Department of Healthcare Surveillance and Bioethics, Section of Pharmacology, Catholic University Medical School, Fondazione Policlinico Universitario A. Gemelli-IRCCS, Rome, Italy; 5Department of Medicine and Surgery, Section of Neurology, Catholic University Medical School, Fondazione Policlinico Universitario A. Gemelli-IRCCS, Rome, Italy
208 -
PO-57 | Early treatment with atogepant improves sleep quality without sleep-related adverse events: a prospective observational study Alberto Boccalini,1 Luigi Francesco Iannone,1,2* Flavia Lo Castro,1 Daria Brovia,1 Marina Romozzi,3,4 Fabrizio Vernieri,5,6 Claudia Altamura,5,6 Simona Guerzoni1 | 1Digital and Predictive Medicine, Pharmacology and Clinical Metabolic Toxicology-Headache Center and Drug Abuse-Laboratory of Clinical Pharmacology and Pharmacogenomics, AOU Policlinico di Modena, Modena, Italy; 2Department of Biomedical, Metabolic, and Neural Science, University of Modena and Reggio Emilia, Modena, Italy; 3Dipartimento Universitario di Neuroscienze, Università Cattolica del Sacro Cuore, Rome, Italy; 4Neurologia, Dipartimento di neuroscienze, Organi di Senso e Torace, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy; 5Headache Unit, Fondazione Policlinico Universitario Campus Bio-Medico, Roma, Italy; 6Università Campus Bio-Medico di Roma, Italy
125 -
PO-16 | Neurophysiological effects of atogepant in high-frequency episodic migraine B. Agostini,1,2 F. Cammarota,1,2 R. De Icco,1,2 V. Grillo,1,2 G. Vaghi,1,2 F. Bighiani1,2, M. Corrado,2 A. Antoniazzi,1,2 M. Giraudo,1,2 A. Solfrizzi,1,2 R. Greco,2 C. Demartini,1,2 A. Zanaboni,1,2 M. Francavilla,1,2 S. Facchetti,1,2 G. Sances,2 C. Tassorelli1,2 | 1Department of Brain and Behavioral Sciences, University of Pavia; 2Headache Science and Neurorehabilitation Unit, IRCCS Mondino Foundation, Pavia, Italy
181 -
PO-51 | Rimegepant combined with valproic acid and botulinum toxin in refractory hemiplegic migraine: a case report Gianni Difonzo, Cinzia Tamborino, Adriana Fallacara, Damiano Paolicelli, Maria Pia Prudenzano | Headache Center, “L. Amaducci” Neurological Clinic, Policlinico General Hospital, Bari, Italy
128 -
PO-13 | HD-EEG Delta connectivity rapidly alters after one month of atogepant in migraine patients Maria Albanese,1,2 Matteo Conti,1 Silvio Bagetta,1 Federico Carparelli,2 Vittoria Carla D’Agostino,2 Fabio Placidi,1,2 Alessandro Stefani,1,2 Nicola Biagio Mercuri,1-3 | 1Department of Systems Medicine, University of Rome Tor Vergata, Rome; 2Neurology Unit, Tor Vergata University Hospital, Rome; 3IRCCS Santa Lucia Foundation, Rome, Italy
205 -
PO-44 | Effectiveness of fremanezumab as preventive treatment of migraine up to 24 months: response rates from the Italian analysis of the PEARL study Alberto Doretti,1 Anna Ambrosini,2 Simone Braca,3 Florindo D’Onofrio,4 Elisa Maria Piella,5 Pinar Kokturk,6 Rosario Iannacchero7 | 1Department of Neurology-Laboratory of Neuroscience, IRCCS, Istituto Auxologico Italiano, Milan, Italy; 2Mediterranean Neurological Institute NEUROMED IRCCS, Pozzilli (IS), Italy; 3Headache Centre, University of Naples “Federico II”, Naples, Italy; 4UOSD Stroke Unit, S.G. Moscati Hospital, Avellino, Italy; 5Neurosciences Department, University of Turin, Turin, Italy; 6Teva Netherlands B.V., Haarlem, The Netherlands; 7Department of Neurology, Headache Center, Regional Hospital “Pugliese-Ciaccio”, Catanzaro, Italy
95 -
OC-18 | Effectiveness of fremanezumab up to 12 months in different subgroups of participants: results from the Italian analysis of the PEARL study Raffaele Ornello,1 Gisella Airola,2 Letizia Curto,3 Diletta Alivernini,4 Chiara Abagnale,5 Pinar Kokturk,6 Yan Tereshko7 | 1Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila; 2Department of Surgical Sciences, Women's Headache Center, University of Turin; 3Neurology Unit, Department of Clinical and Experimental Medicine, University of Pisa; 4Department of Neuroscience, Mental Health and Sensory Organs (NESMOS), Sapienza University of Rome; 5Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome Polo Pontino ICOT, Latina, Italy; 6TEVA Pharmaceuticals Europe B.V., Haarlem, The Netherlands; 7Clinical Neurology, Department of Head-Neck and Neuroscience, Azienda Sanitaria Universitaria Friuli Centrale (ASU FC), Udine, Italy
98 -
PO-38 | Impact of atogepant on achieving best possible quality of life among patient global impression of change responders Cristina Tassorelli,1 Pranav Gandhi,2 Molly Duan,2 Karen Carr,2 Kandavadivu Umashankar,2 Jonathan Stokes,2 Grace Forde,3 Tanya Bilchik,4 Martina Martini*, Rashmi Halker Singh5 | 1University of Pavia, Pavia, Italy; 2AbbVie, North Chicago, IL, USA; 3North American Partners in Pain Management, North New Hyde Park, NY, USA; 4Department of Neurology, Yale School of Medicine, New Haven, CT, USA; 5Mayo Clinic, Phoenix, AZ, USA *Abbvie Srl, Rome, Italy.
171 -
PO-79 | Survey on adherence and tolerability of atogepant used as migraine preventive treatment D.A. Montisano,1 G. Vaghi,2,3 A. Paris,1 R. De Icco,2,3 B. Agostini,2,3 M. Giraudo,2,3 A. Solfrizzi,2,3 C. Tassorelli,2,3 G. Sances,3 L. Grazzi | 1Fondazione IRCCS C.Besta Istituto Neurologico, SSD Headache Center, Milan, Italy; 2University of Pavia, Department of Brain and Behavioral Sciences, Pavia, Italy; 3IRCCS Mondino Foundation, Headache Science & Neurorehabilitation Unit, Pavia, Italy
207 -
OC-14 | Efficacy of eptinezumab during a migraine attack: preliminary data from an Italian multicenter real-world experience (the BEFREE study) Luisa Fofi,1 Claudia Altamura,1 Marilena Marcosano,1 Alberto Doretti,2 Francesca Pistoia,3 Antonio Granato,4 Simona Guerzoni,5 Michele Trimboli,6 Licia Grazzi,7 Danilo Antonio Montisano,7 Gianluca Avino,8 Gabriele Sebastianelli,9 Carla Fasano,10 Elisa Maria Piella,11 Nicoletta Brunelli,1 Luigi Francesco Iannone,5,12 Fabrizio Vernieri1 on behalf of the Italian Headache Registry (RICe) Study Group | 1Neurosonology and Headache Unit, Fondazione Policlinico Campus Bio-Medico, Rome; 2IRCCS Istituto Auxologico Italiano - Department of Neurology and Laboratory of Neuroscience - Milan; 3University of L’Aquila; 4Headache Center, Neurology Clinic, University of Trieste, University Hospital of Trieste; 5AOU Policlinico di Modena; 6Azienda Ospedaliera-universitaria "Renato Dulbecco", Catanzaro; 7Headache Center, Neuroalgology Dpt, IRCCS Foundation "Carlo Besta" Neurological Institute, Milan; 8SOC Neurologia, Ospedale Santo Stefano, USL Toscana Centro, Prato; 9La Sapienza University of Rome Polo Pontino, Latina; 10Headache and Cerebrovascular Diseases Center, Neurology Unit 2, Careggi University Hospital, Florence; 11Department of Neuroscience “Rita Levi Montalcini”, University of Turin; 12Università di Modena e Reggio Emilia, Italy
243 -
PO-35 | Treatment of chronic and episodic migraine with atogepant improves quality of life in patients with comorbid multiple sclerosis: the experience of the Headache Center at Spaziani Hospital, Frosinone Laura Borrello; Fabiana Marinelli; Maria Lorena Marziale; Ilaria Avallone; Fulvio Ferrante; Roberto De Simone | Neurology Unit, Headache Center, Multiple Sclerosis Center, UOC Pharmacy, Spaziani Hospital, Frosinone (FR), Italy
125 -
PO-69 | Three-month atogepant treatment modulates dopaminergic-related functional connectivity in episodic migraine Davide Fedeli,1 Danilo Antonio Montisano,1 Greta Demichelis,1 Giuseppe Ciullo,1,2 Jean Paul Medina Carrion,1 Maria Grazia Bruzzone,1 Emilio Ciusani,1 Alessandra Erbetta,1 Marina Grisoli,1 Erika Guastafierro,1 Domenico D’Amico,1 Alberto Raggi,1 Anna Nigri,1 Licia Grazzi1 | 1Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy; 2University of Parma, Parma, Italy
138 -
OC-13 | Monoclonal antibodies targeting CGRP differently affect sleep and psychiatric comorbidities in reproductive and postmenopausal chronic migraine women Giulia Procopio, Letizia Curto, Antonia Di Chirico, Leonardo Troilo, Gabriele Siciliano, Filippo Baldacci, Sara Gori | Neurology Unit, Department of Clinical and Experimental Medicine, University of Pisa-AOUP, Pisa, Italy
283 -
PO-28 | Sex differences in the response to rimegepant for the treatment of acute migraine attacks – insights from the multicenter GAINER study Raffaele Ornello,1 Gloria Vaghi,2,3 Gabriele Sebastianelli,4 Francesco Casillo,4 Antonio Russo,5 Marcello Silvestro,5 Francesca Pistoia,1 Giorgio Dalla Volta,6 Matteo Cortinovis,6 Alberto Chiarugi,7 Danilo Antonio Montisano,8 Licia Grazzi,8 Maria Pia Prudenzano,9 Sabina Cevoli,10 Edoardo Mampreso,11 Gianluca Avino,12 Marina Romozzi,13 Mariarosaria Valente,14 Carla Fasano,15 Stefania Battistini,16 Antonio Granato,17 Elisa Maria Piella,18 Innocenzo Rainero,18 Federico De Santis,1 Simona Sacco,1 Maria Albanese,19 Michele Trimboli,20 Alberto Doretti,21 Cristina Tassorelli,2,3 Luigi Francesco Iannone,22 Roberto De Icco2,3 on behalf of the Italian Headache Registry (RICe) Study Group | 1Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila; 2Department of Brain and Behavioral Sciences, University of Pavia; 3Headache Science and Neurorehabilitation Unit, IRCCS Mondino Foundation, Pavia; 4Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome Polo Pontino, Latina; 5Headache Centre, Department of Advanced Medical and Surgical Sciences, University of Campania “Luigi Vanvitelli”, Naples; 6Headache Center of Clinical Neurology of Istituto Clinico "Città di Brescia", Brescia; 7Department of Health Sciences, University of Florence; 8Neuroalgology Unit and Headache Center, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan; 9Headache Center, Department of Basic Medical Sciences, Neurosciences and Sense Organs, University of Bari; 10IRCCS Istituto Di Scienze Neurologiche di Bologna, Programma Cefalee e Algie Facciali, Bologna; 11Headache Centre, Neurology - Euganea, Health Unit, Padua; 12Neurology Unit, Ospedale Santo Stefano, USL Toscana Centro, Prato; 13Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome; 14Clinical Neurology, Azienda Sanitaria Universitaria Friuli Centrale, Presidio Ospedaliero Santa Maria della Misericordia, Udine; 15Headache and Facial Pain Center Neurology, AOU Careggi, Florence; 16Department of Medical, Surgical and Neurological Sciences, University of Siena; 17Headache Centre, Clinical Unit of Neurology, School of Neurology, Department of Medicine, Surgery and Health Sciences, University Hospital and Health Services of Trieste, ASUGI, University of Trieste; 18Department of Neurosciences “Rita Levi Montalcini”, University of Turin; 19Department of Systems Medicine, University of Rome Tor Vergata, Rome; 20University Magna Graecia, Catanzaro; 21Department of Neuroscience - Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Milan; 22University of Modena and Reggio Emilia, Modena, Italy
226 -
PO-59 | Questioning online survey-based physiotherapy treatment referral in headache treatment: differences in developed and developing countries D. Onan,1,2 A.K. Erdemoğlu,3 P. Gelener,4 S. Velioğlu,5 S. Ulutaş,6 N. Taşdemir,7 M. Waliszewska-Prosół,8 E. Ekizoğlu,9 M. Straburzyński,10 M. Kodounis,11 B. Raffaelli,12 C. Tana,13 F. De Cesaris,14 R. Messina,15 E.I. Sen,16 S. Ray,17 G. Sebastianelli,18 F. Granella,19 U. Pensato,20 S. Crema,21 S. Cevol,22 K. Chakravarty,23 M. Pia Prudenzano,24 A. Casalena,25 M. Romozzi,26 T. Takizawa,26 W. Rattanawong,27 A. Gantenbein,28 V. Favoni,29 C. Gaul,30 L.F.I. Iannone,31 B. Schäfer,23 D.A. Montisano,33 O. Grosu,34 A.B. de Oliveira,35 F. Puledda,36 V. Romanenko,37 I. Ros González,38 M. Castaldo,39 H. Al-Khazali,40 A. Hassan,41 D. Garcia-Azorin,42 L.-L. Hope Pan,43 R. Gil-Gouveia,44 M. Sanchez del Rio,45 M. Lisicki,46 H.W. Schytz,47 P. Anukoolwittaya,48 T. Mavridis,49 M. Lanteri-Minet,50 D.B. Swerts,51 C. Altamura,52 K. Hirata,53 M. Togha,54 M. Kyung Chu,55 T. Pongpitakmetha,56 M.-H. Bjørk,57 M. Minen,58 K. Skorobogatykh,59 D. Chowdhury,60 A.-M. Torgersen Dalgeir,61 J. Versijpt,62 P. Cras,63 A. Govaerts,64 A. Chiarugi,65 N. Vashchenko,59 L. Dobbels,66 T.S. Monteith,67 F. De Bruyne,68 E. Garay,67 S.L. Sava,69 Z. Salinas,67 M. Nordtveit,70 K. Delmotte,71 A. Gonzalez-Martinez,72 S. Debray,73 C. Deligianni,74 W. De Hertogh,75 R. Castien,76 E. Caronna,77 C. Valerija,78 F. Ahmed,79 G. De la Meilleure,80 L.L. Panneerchelvam,81 G.H. Bringeland,82 R. Ornello,2 S. Sacco2 | 1Yozgat Bozok University, Physiotherapy and Rehabilitation, Ankara, Turkey;2University of L'Aquila, Department of Biotechnological and Applied Clinical Sciences, L'Aquila, Italy;3Clinic of Prof. Dr. Ali Kemal Erdemoğlu, Neurology, Ankara, Turkey;4Elite Research and Surgical Hospital , Nicosia, Cyprus;5Karadeniz Technical University, Department of Neurology, Trabzon, Turkey;6Bahcesehir University, Department of Neurology, İstanbul, Turkey;7Ağrı İbrahim Çeçen University, Department of Neurology, Ağrı, Turkey;8Wroclaw Medical University, Wroclaw, Germany;9Istanbul University, Department of Neurology, Istanbul, Turkey;10University of Warmia and Mazury, Olsztyn, Poland;11National & Kapodistrian University of Athens, First Neurology Department, Eginitio Hospital, School of Medicine, Athens, Greece;12Charité Universitätsmedizin Berlin, Department of Neurology,Headache Center, Berlin, Germany;13SS Annunziata Hospital of Chieti, Chieti, Italy;14Centro Cefalee e Farmacologia Clinica - AOU Careggi , Florence, Italy;15Vita-Salute San Raffaele University, Milano, Italy;16Istanbul University Istanbul Faculty of Medicine, Department of Physical Medicine and Rehabilitation, İstanbul, Turkey;17Department of Neurology, PGIMER, Chandigarh, India;18Sapienza University of Rome, Latina, Italy;19University of Parma, Parma, Italy;20Humanitas University, Milan, Italy;21Fleni Hospital, Buenos Aires, Argentina;22University of Bologna, Bologna, Italy;23Post Graduate Institute Of Medical Education and Research, Chandigarh, India;24AOUC Policlinico, Centro Cefalee - Clinica Neurologica L Amaducci, Bari, Germany;25Centro Cefalee UOC Neurologia, Teramo, Italy;26Keio University School of Medicine, Tokyo, Japan;27King Mongkut's Institute of Technology Ladkrabang, Bangkok, Thailand;28ZURZACH Care, Zürich, Switzerland;30IRCCS Istituto delle scienze neurologiche di Bologna, Bologna, Italy;30Headache Center Frankfurt, Frankfurt, Germany;31Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy, Modena, Italy;32Migraine and Headache Clinic Königstein , Frankfurt, Germany;33SSD Centro Cefalee - Fondazione IRCCS Istituto Neurologico C.Besta, Milan, Italy;34Diomid Gherman Institute of Neurology and Neurosurgery, Kişinev, Moldova;35Center for Clinical and Epidemiological Research, University of Sao Paulo , Sao Paolo, Brazil;36King's College London, London, United Kingdom;37Vita Medical Clinic, Kyiv, Ukraine;38Hospital Clínico Universitario de Valladolid, Vallodolid, Spain;39Parma University, Parma, Italy;40Danish Headache Center, Copenhagen, Denmark;41Cairo University , Cairo, Egypt;42University of Valladolid, Valladolid, Spain;43Brain Research Center, National Yang Ming Chiao Tung University, Taipei, Taiwan;44Hospital da Luz. Lisboa, Lisboa, Portugal;45Clinica Universidad de Navarra, Navarra, Spain;46Mercedes & Martín Ferreyra Institute for Medical Research, Córdoba, Argentina;47University of Copenhagen, Copenhagen, Denmark;48King Chulalongkorn Memorial Hospital, Bangkok, Thailand;49Tallaght University Hospital, Dublin, Ireland;50CHU Nice and Cote D'azur University, Nice, France;51Santa Casa de Sao Paolo, Sao Paolo, Brazil;52Fondazione Policlinico Universitario Campus BIo-Medico, Rome, Italy;53Dokkyo Medical University, Mibu, Tochigi, Japan;54Tehran University, Tehran, Iran;55Yonsei University, Seoul, South Korea;56Chulalongkorn University, Bangkok, Thailand;57University of Bergen , Bergen, Norway;58NYU Langone Health, New York, United States;59University Headache Clinic, Moscow, Russian Federation;60 G B Pant Institute of Post Graduate Medical Education and Research, New Delhi, India;61Haukeland University Hospital, NorHead, Bergen, Norway;62UZ Brussel, Brussel, Belgium;63Universiteit Antwerpen, Antwerpen, Belgium;64Rz Tienen, Tienen, Belgium;65University of Florence, Florence, Italy;Neurology Department İmelda Ziekenhuis, Bonheiden, Belgium;67University of Miami, Miami, United States;68University College Ghent, Ghent, Belgium;69University of Liège, Liege, Belgium;70Haukeland Universitetssykehus, Bergen, Norway;71Universitair Ziekenhuis Leuven, Leuven, Belgium;72Hospital Universitario de la Princesa e Instituto de Investigación Sanitaria Princesa, Madrid, Spain;73Europa Ziekenhuizen, Brussel, Belgium;74Athens Naval Hospital, Athens, Greece;75University of Antwerp , Antwerpen, Belgium;76Vrije Universiteit Amsterdam, Amsterdam, Netherlands;77Vall d'Hebron Hospital, Barcelona, Spain;78Private hospital, Riga, Latvia;79Hull University, Hull, United Kingdom;80VITAZ - General Hospital, Sint-Niklaas, Belgium;81James Cook University Hospital, Middlesbrough, United Kingdom; 82Haukeland University Hospital, Bergen, Norway
106 -
OC-09 | Atogepant in treatment-refractory chronic migraine: is a revision of current criteria for refractory migraine appropriate? Lorenzo Tartaglione, Marcello Silvestro, Ilaria Orologio, Marcella Marziani, Francesco Maurizio Chianese, Pasquale Sozio, Alessandro Tessitore, Gioacchino Tedeschi, Antonio Russo | Headache Center, Department of Advanced Medical and Surgical Sciences (DAMSS), University of Campania "Luigi Vanvitelli", Naples, Italy
260 -
PO-21 | Evaluating the impact of anti-CGRP monoclonal antibodies on retinal features in migraine patients: a retrospective optical coherence tomography study Chiara Serafini,1 Massimo Cesareo,2 Alessio Martucci,2 Marco Lombardo,2 Vittoria Carla D’Agostino,1 Alessandro Stefani,3 Carlo Nucci,2 Nicola Biagio Mercuri,1,3 Maria Albanese1,3 | 1Regional Referral Headache Center, Neurology Unit, Tor Vergata University Hospital, Rome, Italy 2Ophthalmology Unit, Department of Experimental Medicine, University of Rome “Tor Vergata”, Rome; 3Department of Systems Medicine, University of Rome “Tor Vergata”, Rome, Italy
201
1 - 30 of 30 items